Overview

A Rollover Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy

Status:
Completed
Trial end date:
2020-12-21
Target enrollment:
Participant gender:
Summary
This is a rollover study designed to investigate the safety and effectiveness of investigational study drug ARRY-371797 in patients who previously received ARRY-371797 in a study for patients with LMNA-related dilated cardiomyopathy sponsored by Array BioPharma and may, in the Investigator's opinion, derive benefit from continued treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Array BioPharma
Pfizer